No Data
No Data
Berry Genomics (000710.SZ): Board of Directors Secretary Ai Wenlu has resigned.
On July 24th, Gelonhui reported that Berry Genomics (000710.SZ) announced that the board of directors of the company recently received the resignation report of Ms. Aiwenlu, the secretary of the board of directors of the company. Ms. Aiwenlu resigned from the secretary of the board of directors due to job adjustment and will serve in other positions in the company after her resignation. As of the date of this announcement, Ms. Aiwenlu did not directly hold any shares of the company. To ensure the orderly operation of the board of directors, the ninth meeting of the tenth board of directors of the company reviewed and passed the resolution on appointing the secretary of the board of directors of the company, agreeing that Mr. Xu Fei, the director of investor relations of the company, will serve as the secretary of the board of directors of the company and perform the duties of the secretary of the board of directors.
Berry Genomics: 2024 Interim Performance Forecast
Berry Genomics (000710.SZ): Expected net income for the first half of the year to be between 8 million yuan and 12 million yuan.
On July 12th, Glory Hui reported that Berry Genomics (000710.SZ) expects a net income of 8 million to 12 million yuan and a non-net income of 7.5 million to 11.5 million yuan for the first half of the year. 1. During the reporting period, the company continued to improve its operation quality, reasonably control costs, and improve the gross margin level compared to the same period last year. 2. During the reporting period, the company strengthened cost control, and the period cost decreased compared with the same period last year. 3. During the reporting period, the variation loss recognized based on the fair value of the Prenetics shares held by the company decreased compared with the same period last year.
As of June 7th, 2024, Berry Genomics (000710.SZ) had 48,088 shareholders.
Berry Genomics (000710.SZ) stated on the investor interactive platform on June 21 that as of June 7, 2024, the number of shareholders in the company is 48,088.
Berry Gene (000710.SZ): No synthetic biology-related business
Gelonghui, May 24 | Berry Gene (000710.SZ) said on the investor interactive platform that the company is committed to the comprehensive transformation of gene sequencing technology to clinical application, focusing on reproductive health, genetic disease testing, tumor testing, scientific and technological services, etc., and has no synthetic biology-related business yet.
Berry Gene (000710.SZ): No big data artificial intelligence business yet
Gelonghui, April 30 | Berry Gene (000710.SZ) said on the investor interactive platform that the company is committed to the comprehensive transformation of gene sequencing technology to clinical application, focusing on reproductive health, genetic disease testing, tumor testing, scientific and technological services, etc., and there is no big data artificial intelligence business yet.
No Data